Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks

NCT00216177 is registered in ClinicalTrials.gov with Hvidovre University Hospital as lead sponsor.

NCT NCT00216177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00216177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks
Lead sponsor
Hvidovre University Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
September 30, 2005
Completion date
June 30, 2009
Enrollment
112 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis